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ABSTRACT
Trekkers exposed to prolonged hypobaric hypoxia commonly experience weight 
loss, especially loss of lean body mass (LBM). Evidence indicates that protein 
supplementation, specifically leucine, potentially attenuates loss of LBM in a catabolic 
state. This study investigated if leucine supplementation would prevent the loss of LBM 
during prolonged hypoxia. 18 trekkers (M=10 and F=8; age: 47.2 ± 11.5; range: 28-70y), 
completed a 13-day trek in Nepal from Lukla (2180m) to Everest Base Camp (5364m) 
with a mean altitude of 4140m. Participants consumed a 7.0g leucine supplement or an 
isocaloric, isonitrogenous placebo twice daily prior to meals. Body composition, body 
weight, and circumferences of bicep, thigh, and calf were taken pre- and post-trek. The 
participants from both treatments experienced significant loss of LBM and weight loss 
after 13 days at altitudes above 2810m (P< 0.05). However, there was no difference in 
loss of LBM (leucine -1.2 ± 1.6%; placebo -2.1 ± 1.5%), body weight (leucine -2.2 ± 
1.5%; placebo -2.3 ± 2.0%), or circumferences between the groups. Overall, our results 
indicate that under the conditions of this study, leucine did not significantly reduce LBM 
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INTRODUCTION
Healthy individuals exposed to prolonged hypobaric hypoxia (e.g., high altitude) 
commonly experience weight loss (1-3). The majority of this weight loss is comprised of 
lean body mass (LBM). For example, Rose et al. reported a 67% loss of fat-free mass 
compared to a 33% reduction from fat mass (1). Researchers have also observed loss of 
LBM in the lower limb area and a reduction in the calf muscle cross-sectional area (2, 3). 
The negative consequences of LBM loss are decreased physical performance and 
strength, increased risk of injury or edema, and impaired brain function (4). This loss of 
LBM has been attributed primarily to a negative energy balance.
As oxygen availability decreases with ascent to altitude, many factors contribute 
to a negative energy balance including acute mountain sickness (AMS), decreased 
appetite, and increased energy needs (1, 2, 5-12). Acute mountain sickness negatively 
affects energy intake with symptoms of nausea, vomiting, headache, dehydration, and 
loss of appetite (6, 7). Diminished energy intake (43-54%) at high altitudes is a major 
contributor to altitude-induced weight loss (1, 8). The decrease in appetite may be an 
effect of AMS or an increase in leptin (11, 12). The effects of diminished energy intake 
are compounded with increasing energy expenditure as seen with a raise in basal 
metabolic rate with ascent to altitude (9). All these factors taken singularly or collectively 
contribute to weight loss, especially loss of LBM. Maintaining LBM is critical for peak 
performance at high altitudes. As dietary protein is a major contributor to maintaining
nitrogen balance, protein supplementation in a negative energy balance may attenuate the 
loss of LBM.
It has been well documented that dietary protein is a requirement for maintenance 
of muscle mass, with essential amino acids (EAA) acting as a substrate and cell-signaling 
molecules for stimulation of muscle protein synthesis (MPS) (13, 14). Several factors 
affect MPS, including amount of dietary protein, timing of protein ingestion, and source 
of protein intake. Muscle protein synthesis is affected by overall energy balance, amount, 
and quality of dietary protein. Negative energy intake has been shown to suppress MPS 
by decreasing intracellular signaling proteins (15) whereas a higher protein diet 
consumed during a caloric deficit attenuates this reduction in LBM (16). Although 
consumption of protein postexercise is a potent stimulator of MPS, supplemental protein 
consumed steadily throughout the day and during exercise also has merit (16, 17). Protein 
source also affects the rate of MPS. Whey protein appears to be a superior source of 
protein to stimulate MPS (18) since it digests rapidly, increases blood availability of 
amino acids, and has a high concentration of leucine (19). It is well accepted that the 
branch chain amino acids (BCAA) stimulate MPS (20-22) and that leucine has the most 
influential role (23). Leucine is not only a substrate for protein synthesis but also has a 
unique ability to activate the mammalian target of rapamycin (mTOR) signaling pathway, 
a central regulator of MPS (24-29). Numerous factors influence the activation and 
inhibition of mTOR including energy status, amino acid availability, and oxygen status 
(30, 31). Additionally, leucine has been shown to inhibit protein degradation (28, 32).
Numerous studies have examined the effect of protein and leucine 
supplementation on MPS and LBM with varying results. Study conditions include
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negative energy balance, hypoxia, and exercise (16, 26, 33, 34). In a negative energy 
balance, a high protein diet (2.3g/kg vs 1.0g/kg) may prevent loss of LBM in a healthy, 
active, male population (16). Similarly, another study compared the effects of the BCAA 
on MPS with rodents in a negative energy balance and found that leucine had the greatest 
increase on MPS (26). During a 21-day trek at a mean altitude of 3255 meters (m), loss 
of LBM was attenuated in a group consuming a BCAA supplement (5.76g leucine, 2.88g 
isoleucine, 2.88g valine) (33). However, the results of Schena et al. have been disputed 
due to lack of control of food intake and that the diets were not isonitrogenous (35). The 
control supplement in this study was defined as an inert substance possibly not matching 
the protein content in the BCAA supplement. Another study combined an exercise 
program and a leucine-enriched protein supplement (total 39.4g protein / 12.4g leucine) 
for an eight-week period and observed a slight increase in LBM (34).
Although the potential of attenuating loss of LBM with protein supplementation 
has been well investigated at sea level, little research has been done investigating the 
effects of protein supplementation at high altitude. Several studies demonstrate the loss of 
LBM in a state of hypoxia. One study examined leucine as part of a BCAA supplement at 
high altitudes. Other studies have examined the effects of leucine at sea level in a 
negative energy balance and during exercise. There are no studies that have investigated 
the effect of an isolated leucine supplement on a healthy, active population at a mean 
altitude above 4000m for an extended period. Therefore, the purpose of this investigation 
was to determine if leucine supplementation in healthy adult volunteers would prevent or 
attenuate the loss of LBM composition, body weight, and change in bicep, thigh, and calf 




Twenty-eight healthy, physically fit volunteers (15 males, 13 females) were 
recruited for the current study. Participants were identified via email from the 
Wilderness Medical Society (WMS) Mount Everest base camp trek. Participants were 
drawn from two separate treks that were similar in all aspects with exception of the start 
date, with the second trek starting 12 days after the first trek. Participants completed a 
background survey indicating their age, gender, level of physical fitness, prior altitude 
exposure, and symptoms related to altitudes above 2400m. The exclusion criteria 
included those individuals who were excluded from the WMS trek secondary to medical 
or physical limitations identified by a medical professional. The University of Utah 
Institute Review Board for Human Participants approved this study.
Study Design
The present study assessed the effect of a leucine (LEU) supplement versus a 
control (CON) supplement on LBM during a 13-day trek to Everest base camp. In this 
double-blind randomized study, participants consumed a LEU or CON supplement twice 
a day, one prior to breakfast and one prior to lunch. Participants were randomized by age 
and gender to receive either the LEU or CON supplement. Anthropometric (height, body 
weight, and circumferences) and body composition (ultrasound) measurements were
taken pre- and post-trek in Kathmandu, Nepal. During the trek, energy intake was 
recorded in food booklets and energy expenditure was measured using motion detectors.
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Supplement
The participants ingested either LEU or CON twice dally during the 13-day trek 
to Everest base camp (EBC). Each LEU supplement contained 7.0g leucine (14.5g 
protein) and the CON supplement contained 0.3g leucine (11.3g protein). To isolate the 
effects of leucine, the supplements were isonitrogenous. See Table 1 for detailed 
kilocalorie (kcal) and macronutrient content and BCAA content. The supplements were 
chocolate flavored, dry powder mixed with boiled water. Participants consumed the 
supplements prior to meals in order to maximize the absorption of leucine and to 
standardize ingestion. On a daily basis the participants recorded the number of 
supplements consumed in the AMS Assessment Log. Glanbla Foods, International, Twin 
Falls, ID manufactured, labeled and supplied the supplements. The participants and 




Serving size (g) 25.1 22.6
Leucine (g) 7.0 0.3
Nitrogen 2.0 2.0
Calories (kcal) 93.0 92.9
CHO (g) 2.7 3.4
Protein (g) 14.5 11.3
Fat (g) 2.9 4.0
BCAA content
Isoleucine (g) 0. 6 0. 2
Leucine (g) 7.0 0.3
Valine (g) 0.5 0.3
Anthropom etries, Body Composition, and Circumferences
Anthropometrics were measured pre- and post-trek in Kathmandu, Nepal. Height 
was self-reported. Body weight was obtained using a CPW-150 scale (Adam Equipment, 
Inc. Danbury, CT). Participants were weighed (pre- and post-trek) immediately after 
voiding, prior to breakfast, and in lightweight shorts and shirt.
Baseline body composition was measured in Kathmandu either 1 or 2 days prior 
to trek departure. All post-trek measurements were performed within 1 day post-trek in 
Kathmandu. Each trek had its own trained investigator that performed both the pre- and 
post-measurements. Body composition was determined using a handheld ultrasound 
device (BodyMetric Ultrasound Body Composition Tester, IntelaMetrix, Inc., Livermore, 
CA). The device uses ultrasound waves to measure the fat thickness located between the 
skin layer and the muscle layer. The body fat accuracy of the ultrasound technique (UT) 
compared to dual-energy X-ray absorptiometry (DEXA) measurements was found to be 
more accurate and reliable than other methods such as bioelectrical impedance (BIA) or 
air displacement plethysmography (ADP) (36). Hydration status, recent exercise, and 
caffeine consumption are not confounding factors with the ultrasound device. Ultrasound 
measurements included single point and scan data on established skinfold sites (men: 
chest, abdomen, thigh; women tricep, anterior suprailiac, and thigh) (37, 38). Body fat 
was calculated with the Jackson & Pollock (1978) equation for men and the Jackson & 
Pollock (1980) for women. Lean body mass was calculated by subtracting body fat (kg) 
from body weight (kg). As hydration levels may affect body weight, hydration status will 
be measured first void via urine specific gravity strips during the entire trek.
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Circumferences were measured using the International Standards for 
Anthropometric Assessment (ISAK) (39). Circumference measurements included arm, 
thigh, and calf on the right side of the body. Each measurement was performed twice, 
nonconsecutively; if there was a difference >1% between them, a third measurement was 
taken. In the case of a third measurement the data set used the median value of the data.
Diet and Physical Activity
Participants were instructed to keep 3-day food record booklets twice during the 
trek, for a total of 6 days. Food booklets were collected to compare caloric and 
macronutrient intake between LEU and CON groups. Prior to the trek, the participants 
received the food booklets and instructions on how to complete them accurately. The 
food booklets included common teahouse menu items for each meal and estimation of 
portion sizes to assist the participant in keeping accurate records. To decrease participant 
burden, food intake was recorded for two 3-day periods versus the entire trek. Booklets 
were completed at the start of the trek for 3 days and then again for 2 days prior to arrival 
in base camp and 1 day at base camp. The daily energy intake and macronutrient 
composition was determined using Food Processor SQL (version 10.11.1 2012; ESHA 
Research).
Energy expenditure was measured with a motion detector (Actical, Mini Mitter, 
Inc., Bend, OR) provided by the United States Army Research Institute of Environmental 
Medicine (USARIEM). The motion detectors were worn continuously throughout the 13- 
day trek excluding bathing. The Actical tracked and recorded their physical activity in 1- 
minute intervals during the entire 13-day trek. USARIEM developed a macro that 
converted the data into 15-minute intervals. Energy expenditure was calculated using the
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Compendium of Physical Activities equation and included pack weight with body weight, 
(MET x 3.5) x (body weight + pack weight) / 200. Daily energy expenditure was 
calculated for the entire 24 hours.
Statistical Analysis
Data are expressed as means ± SD. A power analysis indicated that a sample size 
of six per treatment group was necessary to detect a 2.2 kg weight difference (± 1.1) 
between groups with 80% power and alpha < 0.05. Participant characteristics were 
calculated using descriptive statistics (mean ± SD). Normality was assessed using a 
Kolmogorov-Smirnov test and all variables were normally distributed. Differences in 
LBM, body weight, body fat percentage, and circumferences were analyzed using 
separate 2 x 2 repeated measures analysis of variance (ANOVA) (time [pre, post] x group 
[LEU, CON]). There were no violations of the sphericity assumption indicated by the 
Mauchley test of sphericity. Participant characteristics, energy intake, energy 
expenditure, and supplement compliance and consumption were analyzed using 
independent ^-tests. The level of significance for all analyses was set at P  < 0.05. 




A total of 18 participants completed the study (LEU: n=8; CON: n=10). 
Participant characteristics are listed in the Table 2. There were no significant differences 
in baseline characteristics and pre-trek measurements between the groups. Attrition rate 
was 36%. Participants withdrew from the study primarily due to acute mountain sickness 
and altitude and/or food-related gastrointestinal distress.
Supplement
Supplements were consumed twice daily for 13 days of the trek. Complete 
supplement data was available for 13 of the participants (LEU n=6 and CON n=7).
Table 2
Baseline Participant Characteristics1
LEU (n=8) CON (n=10) ALL (N=18)
Female 4 4 8
Male 4 6 10
Age (year) 44.5 ± 10.4 49.4 ± 12.3 47.2 ± 11.5
Body weight (kg) 76.9 ± 15.2 76.7 ± 13.7 76.8 ± 14.0
Height (cm) 172.4 ± 9.7 175.0 ± 9.7 173.9 ± 9.5
BMI (kg/m2) 25.7 ± 3.6 24.9 ± 2.5 25.2 ± 3.0
Lean mass (kg) 58.1 ± 11.2 59.4 ± 11.1 58.8 ± 10.8
Body fat (kg)
1 a ,,, , 18.8 ± 6.9 17.3 ± 5.3 18.0 ± 5.9All values are ± mean SD. No significant differences between groups.
Overall compliance (e.g., 2 packets per day) was 93% ± 12% with LEU at 89% ± 17% 
and CON at 96% ± 6%. There was no significant difference in compliance between the 
two groups. Average leucine consumption for LEU was significantly greater than CON 
(12.5 ± 2.5 g/day and 0.7 ± 0.0 g/day, respectively (P < 0.05).
Body Composition and Circumferences
Prior to the intervention, lean mass (kg), body weight (kg), and body fat (kg) did 
not differ between groups (Table 3). To standardize the differences in body composition 
between the participants, percentage change was calculated by dividing the measurement 
difference (post - pre) by the pre-trek measurement. The participants from both 
treatments experienced significant loss of LBM and body weight after 13 days at a mean 
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Figure 1. Body composition loss percentage calculated by dividing loss of body weight, 
LBM, and body fat by pre-trek measurements. *Significant loss (P < 0.05).
For all participants, LBM loss was 1.0 ± 0.9 kg (1.7% ± 1.6%), body weight loss was 1.9 
± 1.5 kg (2.2% ± 1.7%), and body fat loss was 0.8 kg ± 1.2 (4.0% ± 6.9%). However, 
there was no significant difference in LBM, body weight, or body fat between LEU and 
CON (Figure 1). As hydration level may affect overall body weight, hydration status was 
determined via urine specific gravity strips. There was no difference in hydration status 
between the groups. For the LEU group, LBM loss was 0.8 ± 1.0 kg (1.2% ±1.6%), body 
weight loss was 1.8 ± 1.4 kg (2.2% ± 1.5%), and body fat loss was 1.1 kg ± 1.4 (5.4% ±
8.1%). For the CON group, LBM loss was 1.2 ± 0.9 kg (2.1% ± 1.5%), body weight loss 
was 1.9 ± 1.7 kg (2.3% ± 2.0%), and body fat loss was 0.6 kg ± 1.1 (2.9% ± 5.9%). For 
all participants, LBM was 56% of body weight loss and body fat was 44% of body 
weight loss. For the LEU group, LBM and body fat was 42% and 58%, respectively, of 
body weight loss. For the CON group, LBM and body fat was 66% and 34%, 
respectively, of body weight loss. Similarly, participants from both treatments saw 
significant loss in bicep, thigh, and calf circumferences (P < 0.05), although there was no 
difference in circumferences between the LEU and CON groups (Table 4).
Diet and Physical Activity 
Energy intake and macronutrient composition was determined for each day the 
participants had complete data in the food booklet. The daily average was then calculated 
based on the number of days completed. Completion of food records was as follows, 6 
days (n=14), 5 days (n=1), and 3 days (n=3). Daily averages for energy intake and 
macronutrient by group and overall are listed in Table 5. There were no significant 
differences in energy intake and grams of carbohydrates, protein and fats between the two
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Table 3
Body Composition Pre- and Postmeasurements1
LEU (n=8) CON (n=10) ALL (N=18)
Pre Post Pre Post Pre Post
Body weight (kg) 76.9 ± 15.2 75.1 ± 14.3 76.7 ± 13.7 74.8 ± 12.6 76.8 ± 14.0 75.0 ± 12.9*
Lean mass (kg) 58.1 ± 11.2 57.3 ± 10.8 59.4 ± 11.1 58.2 ± 10.9 58.8 ± 10.8 57.8 ± 10.6*
Body fat (kg) 18.8 ± 6.9 17.8 ± 6.7 17.3 ± 5.3 16.7 ± 4.6 18.0 ± 5.9 17.2 ± 5.5
1All values mean ± SD. *Significant decrease (P < 0.05)
Table 4
Anthropometrics Pre- and Postmeasurements1
LEU (n=8) CON (n=10) ALL (N=18)
Pre Post % Difference Pre Post % Difference Pre Post % Difference
Bicep (cm) 32.0 ± 2.8 31.2 ± 2.6 -2.4 ± 1.8 34.1 ± 6.1 33.5 ± 6.4 ■-2.0 ± 1.9 33.2 ± 4.9 32.5 ± 5.1 -2.2 ± 1.8*
Thigh (cm) 53.2 ± 3.8 52.9 ± 3.4 -0.6 ± 1.2 50.5 ± 6.3 49.8 ± 5.6 -1.2 ± 2.0 51.7 ± 5.4 51.2 ± 4.9 -0.9 ± 1.7*
Calf (cm) 38.9 ± 1.9 38.6 ± 2.1 -0.9 ± 1.3 37.5 ± 3.9 37.1 ± 3.8 ■-1.0 ± 1.2 38.1 ± 3.2 37.7 ± 3.1 -1.0 ± 1.2*
'All values mean ± SD. *Significant decrease (P < 0.05)
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groups. Additionally there was no significant difference in macronutrient distribution 
between the two groups (Table 6). Based on pre-trek participant weight average, daily 
energy intake per kg for all participants was 25.2 ± 6.0 kcal/kg, carbohydrate was 3.1 ± 
0.8 g/kg, and protein was 1.1 ± 0.2 g/kg. The LEU group was 25.8 ± 7.3 kcal/kg, 
carbohydrate was 3.2 ± 0.9 g/kg, and 1.2 ± 0.3 g/kg protein and CON group was 24.7 ± 
5.0 kcal/kg, carbohydrate was 3.1 ± 0.7 g/kg, and 1.0 ± 0.2 g/kg protein. There were no 
significant differences in kcal/kg, carbohydrate g/kg, and protein g/kg between the two 
groups. Without the supplement the amount of protein per body weight was significantly 
lower with all participants (N=18) at 0.8 ± 0.2 g/kg protein, the LEU group at 0.8 ± 0.2 
g/kg protein, and the CON group at 0.7 ± 0.1 g/kg protein.
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Table 5
Energy Intake by Kcal and Macronutrient Composition1
Daily Average
LEU (n=8) CON (n=10) ALL (N=18)
kcal 1895.5 ± 378.3 1879.3 ± 489.9 1886.5 ± 431.4
CHO (g) 236.0 ± 49.9 235.4 ± 67.7 235.7 ± 58.8
FAT (g) 68.3 ± 16.1 71.1 ± 22.5 69.8 ± 19.4
PRO (g) 86.0 ± 14.7 76.9 ± 10.2 80.9 ± 12.9
1All values are mean SD. Participants completed two 3-day food records during the 13- 
day trek, days 1-3 and days 8-10. No significant differences between groups.
Table 6
Energy Intake by Macronutrient Distribution1
Daily Average
LEU (n=8) CON (n=10) ALL (N=18)
CHO 50% 50% 50%
FAT 32% 34% 33%
PRO 18% 16% 17%
Participants completed two 3-day food records during the 13- 
day trek, days 1-3 and days 8-10. No significant differences
between the groups.
Mean energy expenditure did not differ between the groups. Overall daily energy 
expenditure (N=16) was 3737 ± 686 kcal/day. LEU (n=7) mean energy expenditure was 
3653 ± 641 kcal/day and CON (n=9) was 3803 ± 750 kcal/day. Twelve participants 
completed the full 6-day food record and had full energy expenditure results. Figure 2 
illustrates the negative energy balance between energy expenditure and energy intake for 
these 12 participants. Average daily deficiency (N=12) was 1575 ± 651 kcal/day for the 6 
days that food records were kept.
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Participants excluded if they did not complete the full 6-day food record or did not have a 
complete energy expenditure value.
DISCUSSION
The current study investigated the effects of leucine supplementation on LBM 
during an extended trek at a mean altitude of 4139m. Supplementation with 7g of leucine 
twice daily (daily total=14g) during the 13-day trek did not attenuate the loss of LBM or 
body weight in the LEU group when compared to the CON group. Additionally, leucine 
supplementation did not attenuate the decrement in bicep, thigh, and calf circumferences. 
However, it is of interest that in as little as 13 days at high altitude, participants saw a 
significant loss of LBM, body weight, but not body fat and significant decreases in bicep, 
thigh, and calf circumferences.
Current evidence proposes that protein and/or leucine supplementation can 
attenuate the loss of LBM under conditions such as hypoxia and negative energy balance; 
conditions noted in the present study. Our data are in contrast to Schena et al. (33) who 
found that BCAA (5.76 leucine, 2.88g isoleucine, 2.88g valine) attenuated the loss of 
LBM during a 21-day trek at a mean altitude of 3255m. One possible difference between 
the studies was that our experiment was conducted at a higher altitude (+914 m).
Hypoxia may negatively affect mTOR function, subsequently impairing MPS. Vigano et 
al. (31) investigated the effect of hypoxia on the mTOR signaling pathway in humans 
traveling from sea level to 4559m. After only 6 days, the study found a significant 
decrease in the expression level of mTOR after long-term hypoxic exposure. Therefore, it 
is possible that MPS may have been suppressed to a greater extent due to the higher 
altitude (e.g., hypoxia) in our study than Schena et al. (33).
Additionally, our data suggest a negative energy balance. Walker et al. (34) found 
a slight increase of LBM with an 8-week leucine supplementation in a population that 
maintained their overall energy balance. This is in contrast to our study, which indicated 
a significant caloric deficit. In a negative energy balance with low carbohydrate 
availability, dietary protein or existing protein tissue may be catabolized for energy 
purposes. BCAA, and in particular leucine, is a primary fuel source for skeletal muscle 
for stimulating MPS and maintaining LBM (20-22). If dietary protein is being utilized for 
energy, this may explain a lack of effect of leucine supplementation on attenuating loss of 
LBM.
Our data also found a low amount of carbohydrate intake during the trek. During 
high levels of physical activity, as evidenced in our study with a mean energy 
expenditure of 3737 ± 686 kcal/day, recommended levels of carbohydrates are 7-10 g/kg 
of body weight to maintain glycogen stores (40). The mean carbohydrate intake during 
the trek was only 3.1 ± 0.8 g/kg of body weight. A diet with a carbohydrate intake of less 
than 5 g/kg results in decreased muscle glycogen stores (41). It is likely that at this level 
of inadequate carbohydrate consumption, dietary protein, particularly leucine and BCAA, 
was being metabolized for energy rather than being used for generating muscle tissue. 
Howarth et al. (42) induced a glycogen-depleted state with a low carbohydrate diet and 
found that during endurance exercise, whole body leucine oxidation was higher in the 
low carbohydrate diet than the high carbohydrate diet. In the current study, the 
participants were most likely in a glycogen-depleted state and it is probable that dietary 
protein, and specifically leucine, was catabolized for energy rather than for synthesizing 
muscle tissue.
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Additionally, the overall intake of dietary protein may have been insufficient to 
stimulate MPS in a negative energy balance. In Mettler et al. (16), the control group 
received 1.0 g/kg of protein while the treatment group received 2.3 g/kg of protein in a 
60% caloric deficiency with the treatment group indicating attenuation of LBM after four 
weeks of supplementation. In the current study, the overall protein intake for all 
participants was 1.1 ± 0.2 g/kg protein of body weight. The reduced level of protein 
intake combined with the observed caloric deficit may have lessened the impact o f 
leucine supplementation on LBM. General guidelines for endurance athletes recommend 
a higher intake of protein, 1.2-1.4 g/kg of body weight to maintain adequate nitrogen 
balance (43). Furthermore, weight loss studies indicate that a diet high in protein, 1.6 
g/kg, provides a more efficient loss of fat mass and preservation of LBM than high 
carbohydrate diets (44). Another point to consider is that both supplements in our study 
provided an additional 29.0 g protein (LEU) and 22.6 g protein (CON) per day. Without 
either supplement, average daily protein intake decreased significantly (1.1 ± 0.2 g/kg to
0.8 ± 0.2 g/kg protein per body weight) and may have prevented even greater loss of 
LBM than if no supplement was consumed. This is another difference between Schena et 
al. (33) and our study. In Schena et al., the control supplement was defined as an inert 
substance and the protein amount may not have been matched between the groups. Thus, 
the attenuation of LBM may be attributable to the difference in overall protein intake 
versus the influence o f solely the BCAAs.
The current study identified a significant loss o f LBM, body weight, and 
decreases in arm, thigh, and calf circumferences in as little as 13 days at a mean altitude 
of 4139 m (p<0.05). Loss of LBM (1.7 ± 1.6%) and body weight in the current study is
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similar to trends found in other high altitude studies (1, 2, 8, 9, 33). Our results for all 
participants (56% from fat-free mass (FFM) and 44% from fat mass (FM)) indicate that 
LBM represented a majority of the body mass loss similar to Rose et al. (67% from FFM 
and 33% from fat mass FM). Fulco et al. (45) investigated the effect of a 1500 kcal per 
day deficit for 21 days and also saw a significant loss of body weight with 69% from 
LBM. This in contrast to two other studies that indicated a majority of FM loss, with 67% 
FM and 33% FFM (2) and 90% FM and 10% FFM in the placebo group (33). Although 
not statistically significant, the LEU group (42% from FFM and 58% FM) had less FFM 
loss than the CON group (66% from FFM and 34% from FM). Of importance in the 
current study is the timeframe of the weight loss and the mean altitude of the trek.
Several of the high altitude weight losses occurred at higher altitudes and for longer 
periods (21-40 days). Our study indicated loss of significant body weight within only 13 
days and at a mean altitude of 4139m.
A likely contributor to loss of LBM and body weight at high altitude was a 
negative energy balance with our results matching and exceeding those of previous 
studies. In the current study, a mean caloric deficit of 1575 ± 651 kcal/day was observed 
for the 6 days that food records were kept. This was approximately 43% of measured 
total daily energy expenditure. Although the caloric deficit observed in the 6-day food 
booklet is a snapshot of the entire trek, it likely represents the remaining 7 days of the 
trek. Previous studies have noted similar caloric deficits. Westerterp et al. (2) found a 
deficit of 1385 ± 430 kcal/day and Westerterp-Plantenga et al. (8) a deficit of 955 ± 358 
kcal/day. Rose et al. (1) also saw a similar trend. Again, this caloric deficit together with
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low carbohydrate availability, may have attenuated the effect of the leucine 
supplementation on MPS.
Our study also supports previous research on loss of LBM primarily in the limbs 
(1-3, 33). Bicep, thigh, and calf circumferences decreased significantly in 13 days (P 
<0.05). Several studies have observed similar results. Rose et al. (1) reported decreases in 
upper arm, thigh, and calf circumferences and Westerterp et al. (2) observed a 6% loss in 
lower limb anthropometry. Schena et al. (33) found a significant decrease in cross­
sectional area of the arm and thigh while Edwards et al. (3) specifically saw a significant 
decrease in the calf cross-sectional area. In both the present data and past data, significant 
muscle atrophy in the limbs was observed signifying loss of LBM and catabolism of 
muscle protein during prolonged periods to high altitude.
Strengths and Limitations
Strengths of the current study include that it was as a field study versus in a 
hypobaric chamber, allowing for free-living conditions rather than a restricted 
environment. Additionally, the study took place in Nepal with a mean altitude of 4139m, 
which provided higher altitudes than those available in the United States. Of those 
participants that completed the study, compliance was strong for both completion of food 
booklets and supplement consumption. Lastly, the use of the ultrasound for measurement 
of LBM provides an accurate measurement without concern for hydration status.
There were several limitations to the present study. Unlike in a laboratory setting, 
external factors were difficult to control. The extreme altitude environment resulted in 
several AMS, HAPE (high altitude pulmonary edema), and gastrointestinal problems that 
contributed to attrition. The international location was also a limiting factor. Due to the
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cost, remoteness, and length of the trek, the sample size was restricted. Although the food 
booklets were quite detailed, it is generally noted that participants frequently under report 
energy intake when completing food records. The sample size was small, not allowing for 
a third group that would have received an isocaloric supplement with no protein content. 
Additionally, a post hoc power analysis indicated that with current LBM loss and 
standard deviation, each group needs a sample size of 90 participants. An alternative 
would be to decrease confounding factors by limiting participants by age, gender, BMI, 
or body fat. This would diminish the variability amongst the participants and minimize 
the standard deviation, which in turn decreases the sample size to detect a 2.2 kg 
difference between the groups. Lastly, leucine supplement dose was not based on kg of 
body weight. Consequently, some participants were receiving much g/kg higher doses 
than others. Due to the nature of this study (e.g., field vs. laboratory) it was not feasible to 
package the leucine supplements in varying amounts. Future studies may consider 
prescribing separate standardized doses to males and females or per kg of body weight.
Conclusion
In conclusion, our data did not indicate an attenuation of LBM at high altitudes 
with 7.0 g leucine supplement consumed twice daily compared to the placebo group. It is 
possible that the negative energy balance and suboptimal carbohydrate and protein intake 
may have negatively affected the potential impact of leucine supplementation on MPS.
Of importance is the loss of LBM within such a short duration of 13 days at mean altitude 
of 4319m. Further research is warranted to investigate a leucine supplement in a negative 
energy balance with a higher level of overall protein intake and under hypoxic conditions 




ALTITUDE AND ACTIVITY BACKGROUND SURVEY FORM
INSTRUCTIONS: Please complete all items to the best of your knowledge. If you have any 
questions please ask the investigators for clarification. Thank you for your cooperation.
SUBJECT ID# (to be filled out by investigator):_______  TODAY'S DATE: __________________
day month year
PART 1: BASIC INFORMATION
1. Age: _____________  Date of Birth:
2. Gender: ______ Male _______ Female
3. Racial Identity (check the best category that applies to you):
________ American Indian / Alaska Native
________ Asian
________ Black / African American
________ Native Hawaiian / Pacific Islander
________ White
4. Ethnicity (check the best category that applies to you):
________ Not Hispanic or Latino
________ Hispanic or Latino
5. Height: , (e.g. without shoes) (ft./in.)
6. Weight: , (e.g. without shoes) (ft./in.)
7. Your Place of Birth:
(Town) (State) (Nation)
8. Current Place of Residence:
9. Do you smoke?
10. Do you chew tobacco?
(Town) (State) (Nation)





11. Do you have any food allergies?________  Yes, if yes, food item(s):
___________  No
12. Do you use any dietary supplements (including protein powders)? ___________  Yes; if
yes, list product/daily dosage: ________________________________________________
________ No
13. Are you taking any medications? If so, please list medication.
PART 2: ALTITUDE EXPERIENCE
This section related to your experience at altitudes of 8,000 feet or more above sea level. If you 
have spent at least 8 or more hours at an altitude of 8,000 feet or above, please answer 
questions 11 -  15. (Note the following examples of 8,000 and greater elevations: Grand Canyon, 
Yellowstone, and Yosemite National Parks; Buena Vista, CO; Crested Butte, CO; Vail, CO; 
Breckenridge, CO).
13. Have you ever been at an altitude of 8,000 feet or above for a day or more?
________ Yes
________ No (if no, go directly to question #18.)
14. How long were you at an altitude of 8,000 feet or above?
________ 0 -  8 hours
________ Greater than 8 hours
15. Have you ever slept one or more days at an altitude of 8,000 feet or above?
________ Yes
________ No
16. How many day have you spent at an altitude of 8,000 feet or above in the past 60 days? 
  Less than 2 weeks (< 14 days)
________ The last 2 weeks (~ 14 days)
________ The last 4 weeks (~ 30 days)
________ The last 8 weeks (~ 60 days)
17. When you were at an altitude of 8,000 feet or above, at anytime did you ever experience 
any of the following symptoms? (Check as many answers as appropriate.)
________  not affect at all ___________  nausea ___________  loss of appetite
________ headache ___________  weakness ___________  irritable
urinate more urinate less dizziness
tired ___________  could not sleep
N/A *(not applicable)
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PART 3: ACTIVITY HISTORY
18. How many times per week do you currently take part in strength conditioning (ex., weight 
lifting and resistance training) or calisthenics (example: sit-ups and push-ups)? (Check only 
one answer.)
________ 1 day per week
________ 2 -  4 days per week
________ More than 4 days per week
________ Do not participate (skip to question 21)
19. For each strength conditioning or calisthenics session, how long do you participate? (List 
each activity).
________ Less than 30 minutes: _______________________________________________
________ 30 -  60 minutes: _______________________________________________
________ Great than 60 minutes: _______________________________________________
20. Please check the overall degree of intensity for the above-mentioned strength conditioning 





21. How many times per week do you currently take part in aerobic conditioning (example: 
running, walking, cycling, playing basketball, and rowing)? (Check only one answer.) 
  1 day per week
________ 2 -  4 days per week
________ More than 4 days per week
________ Do not participate (skip to question 23)
22. For each aerobic conditioning session, how long do you participate? (List each activity.)
________ Less than 30 minutes: _______________________________________________
________ 30 -  60 minutes: _______________________________________________
________ Great than 60 minutes: _______________________________________________
23. Please check the overall degree of intensity for the above-mentioned aerobic conditioning 






For military personnel only:
24. For your appropriate military service (e.g., Army, Navy, Marines or Air Force), estimate your 
most recent run time: (List only one answer.)
________ Time (min./sec.) to run 2 miles (Army)
________ Time (min./sec.) to run 1.5 miles (Navy)
________ Time (min./sec.) to run 3 miles (Air Force)




Leucine Study Food Record
SID#:
Please write down everything you eat for three days. Include the name of the food, description if 
necessary, and the amount. In order to compare treatment groups, we need as accurate of record as 
you can complete. You will be interviewed at the end of each day of recorded dietary intake.
Note: daily beverages will be tracked in AMS log book on hydration page.
Food records will be completed for 3 days at 2 time points: 
FIRST TIME PERIOD
1) Fly to Lukla Trek to Phakdinq
2) Namche
3) Namche — Hike to Khumjunq, Syanqboche 
SECOND TIME PERIOD
1) Gorakshep-Kalapotthar-Gorakshep
2) Everest Base Comp
3) Everest Base Camp
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Day:___________  Date:_________________ Location
Check Breakfast item -  circle specific Amounts -  circle one
Fried egg Egfis: 1 2 3 *\
Egg om elet 1 2 3 OR Cups:_____1/2 1
Scram bled eggs 1 2 3 OR Cups:_____1/2 1
Fried potato w/eggs Cups: 1/4 1/2 3/4 1 V i  2
Porridge -  plain or cinnam on Cups: 1/4 1/2 3/4 1 I K  2
M uesli - plain or w/hot milk Cups: 1/4 1/2 3/4 1 I K  2
Cornflakes Cups: 1/4 1/2 3/4 1 IK  2
Rice pudding Cups: 1/4 1/2 3/4 1 IK  2
French toast Slices: 1 2 3 4
Tibetan Bread or toast w/jam Slices: 1 2 3 4
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Note: beverage consumption and supplements are tracked in the daily fluid log (AMS log book),
Day:_____________  Date:_________________ Location
Check Lunch item -  circle specific Amounts -  circle one
Soup — tomato / chicken / garlic Cups: 1/4 1/2 3/4 1 IK 2
Fried Noodles — plain or mixed Cups: 1/4 1/2 3/4 1 IK 2
Curry — rice or chicken Cups: 1/4 1/2 3/4 1 IK 2
Sizzlers -  chicken or yak Cups: 1/4 1/2 3/4 1 IK 2
Tuna sandwich Sandwiches: 1/2 1 IK 2
Cheese pizza -  plain / mushroom Slices: 1 2 3 4
Spaghetti Cups: 1/4 m 3/4 1 IK 2
Fried potatoes w/eggs Cups: 1/4 1/2 3/4 1 IK 2
Potato Momo (dumplings) Dumplings: 1 2 3 4
Mashed potatoes Cups: 1/4 1/2 3/4 1 IK 2
Dal Bhat (lentils + rice) Cups: 1/4 1/2 3/4 1 IK 2
Plain rice Cups: 1/4 1/2 3/4 1 IK 2
French fries or Potato chips Cups: 1/4 1/2 3/4 1 IK 2
Tibetan bread or Chapati Slices: 1 2 3 4
Other — specify Amount (write in):
Other — specify Amount (write in):
Note: beverage consumption and supplements are tracked in the daily fluid log (AMS log book),
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Day:____________  Date: _________________ Location
Check Snack item -  circle specific Amounts -  circle one
Potato chips Bag sizei 1 oz 2 oz 3 oz 4 oz
Energy bar - specify Barsize^ lo z  2 oz 3 oz 4oz
Energy bar - specify Barsize^ lo z  2 oz 3 oz 4 oz
Candy bar - specify Barsize^ .lo z  2 oz 3 oz 4 oz
Candy bar - specify Bar size;. JLo z  2oz 3 oz 4 oz
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Note: beverage consumption and supplements are tracked in the daily fluid log (AMS log book),
Date: Location:
Check DINNER item -  circle specific Amounts -  circle one
Soup — tomato / chicken / garlic Cups 1/4 1/2 3/4 1 i a i
Fried Noodles -  plain or mixed Cups 1/4 1/2 3/4 1 l  y, 2
Curry — rice or chicken Cups 1/4 1/2 3/4 1 m 2
Sizzlers — chicken or yak Cups 1/4 1/2 3/4 1 V/z 2
Tuna sandwich Sandwiches: 1/2 1 IK 2
Cheese pizza -  plain / mushroom Slices: 1 2 3 4
Spaghetti Cups: 1/4 l7 2 3/4 1 V/z 2
Fried potatoes w/eggs Cups: 1/4 1/2 3/4 1 154 2
Potato Momo (dumplings) Dumplings: 1 2 3 4
Mashed potatoes Cups 1/4 1/2 3/4 1 i a 2
Dal Bhat (lentils + rice) Cups 1/4 1/2 3/4 1 m 2
Plain rice Cups 1/4 1/2 3/4 1 VA 2
French fries or Potato chips Cups 1/4 1/2 3/4 1 V/z 2
Tibetan bread or Chapati Slices: 1 2 3 4
Other -  specify Amount (write in):
Other -  specify Amount (write in):
Note: beverage consumption and supplements are tracked in the daily fluid log (AMS log book).
APPENDIX C
AMS ASSESSMENT LOG
AMS Assessment Log Book
NAME: _______________________________
SID#: _______________________________
Please carry your AMS log book in your trail pack and complete every day.
Directions for booklet usage:
• AMS LOG (2 pages) -  before breakfast
• Supplement packets and daily hydration (1 page) -  throughout the day
• Energy Bars, medications, and vitamins/supplements (1 page) -  throughout the day
• AMS (2 pages) -  before bed
Medications include any type of medicine, vitamin, or supplement. Please include brand names (if 
available), dosage and timing.
Again, thank you for your participation.
DAY & DATE: TIME: LOCATION: ALT:
Check Study Packets Amounts -  circle one
Study Packets Amount: 0 1 2
Times:
Check Fluid Amounts -  circle one
Water Ounces: 16 32 64 96 128 Other
Sports drink (specify) Ounces: 8 16 24 32 64 Other:
Soda (specify) Ounces: 8 16 24 32 64 Other:
Tea Ounces: 4 6 8 12 16 Other
Coffee Ounces: 4 ~6 8 12 16 Other
Hot Cocoa Ounces: 4 ~6 8 12 16 Other
Juice (specify) Ounces: 4 6 8 12 16 Other
Milk Ounces: 4 C 8 12 16 Other
Beer (specify) Ounces: 4 6 8 12 16 Other
Wine (specify) Ounces: 4 6 8 12 16 Other
Other -  specify Amount (write in):




1. Rose MS, Houston CS, Fulco CS, Coates G, Sutton JR, Cymerman A. Operation 
Everest. II: Nutrition and body composition. J Appl Physiol 1988;65(6):2545-51.
2. Westerterp KR, Kayser B, Brouns F, Herry JP, Saris WH. Energy expenditure 
climbing Mt. Everest. J Appl Physiol 1992;73(5):1815-9.
3. Edwards LM, Murray AJ, Tyler DJ, et al. The effect of high-altitude on human 
skeletal muscle energetics: P-MRS results from the Caudwell Xtreme Everest 
expedition. PloS one 2010;5(5):e10681. doi: 10.1371/journal.pone.0010681.
4. Carbone JW, McClung JP, Pasiakos SM. Skeletal muscle responses to negative 
energy balance: effects of dietary protein. Adv Nutr 2012;3(2):119-26. doi: 
10.3945/an.111.001792.
5. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Amer J Clin 
Nutr 2010;91(4):1123S-7S. doi: 10.3945/ajcn.2010.28608A.
6. Imray C, Wright A, Subudhi A, Roach R. Acute mountain sickness: 
pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 2010;52(6):467- 
84. doi: 10.1016/j.pcad.2010.02.003.
7. Hamad N, Travis SP. Weight loss at high altitude: pathophysiology and practical 
implications. Eur J Gastroenterol Hepatol 2006;18(1):5-10.
8. Westerterp-Plantenga MS, Westerterp KR, Rubbens M, Verwegen CR, Richelet 
JP, Gardette B. Appetite at "high altitude" [Operation Everest III (Comex-'97)]: a 
simulated ascent of Mount Everest. J Appl Physiol 1999;87(1):391-9.
9. Butterfield GE, Gates J, Fleming S, Brooks GA, Sutton JR, Reeves JT. Increased 
energy intake minimizes weight loss in men at high altitude. J Appl Physiol 
1992;72(5):1741-8.
10. Reynolds RD, Lickteig JA, Deuster PA, et al. Energy metabolism increases and 
regional body fat decreases while regional muscle mass is spared in humans 
climbing Mt. Everest. J Nutr 1999;129(7):1307-14.
11. Shukla V, Singh SN, Vats P, Singh VK, Singh SB, Banerjee PK. Ghrelin and 
leptin levels of sojourners and acclimatized lowlanders at high altitude. Nutr 
Neurosci 2005;8(3):161-5.
30
12. Tschop M, Strasburger CJ, Hartmann G, Biollaz J, Bartsch P. Raised leptin 
concentrations at high altitude associated with loss of appetite. Lancet 
1998;352(9134):1119-20. doi: 10.1016/S0140-6736(05)79760-9.
13. Phillips SM, Van Loon LJ. Dietary protein for athletes: from requirements to 
optimum adaptation. J Sports Sci 2011;29 Suppl 1:S29-38. doi: 
10.1080/02640414.2011.619204.
14. Drummond MJ, Glynn EL, Fry CS, Timmerman KL, Volpi E, Rasmussen BB. An 
increase in essential amino acid availability upregulates amino acid transporter 
expression in human skeletal muscle. Am J Physiol Endocrinol and Metab 
2010;298(5):E1011-8. doi: 10.1152/ajpendo.00690.2009.
15. Pasiakos SM, Vislocky LM, Carbone JW, et al. Acute energy deprivation affects 
skeletal muscle protein synthesis and associated intracellular signaling proteins in 
physically active adults. J Nutr 2010;140(4):745-51. doi: 10.3945/jn.109.118372.
16. Mettler S, Mitchell N, Tipton KD. Increased protein intake reduces lean body 
mass loss during weight loss in athletes. Med Sci Sports Exerc 2010;42(2):326-
37. doi: 10.1249/MSS.0b013e3181b2ef8e.
17. Phillips SM. The science of muscle hypertrophy: making dietary protein count. 
Proc Nutr Soc 2011;70(1):100-3. doi: 10.1017/S002966511000399X.
18. Tang JE, Moore DR, Kujbida GW, Tarnopolsky MA, Phillips SM. Ingestion of 
whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein 
synthesis at rest and following resistance exercise in young men. J Appl Physiol 
2009;107(3):987-92. doi: 10.1152/japplphysiol.00076.2009.
19. Hulmi JJ, Lockwood CM, Stout JR. Effect of protein/essential amino acids and 
resistance training on skeletal muscle hypertrophy: A case for whey protein. Nutr 
Metab (Lond) 2010;7:51. doi: 10.1186/1743-7075-7-51.
20. Garlick PJ, Grant I. Amino acid infusion increases the sensitivity of muscle 
protein synthesis in vivo to insulin. Effect of branched-chain amino acids. 
Biochem J 1988;254(2):579-84.
21. Wolfe RR. Regulation of muscle protein by amino acids. J Nutr 
2002;132(10):3219S-24S.
22. Cuthbertson D, Smith K, Babraj J, et al. Anabolic signaling deficits underlie 
amino acid resistance of wasting, aging muscle. FASEB J 2005;19(3):422-4. doi: 
10.1096/fj.04-2640fje.
23. Garlick PJ. The role of leucine in the regulation of protein metabolism. J Nutr 
2005;135(6 Suppl):1553S-6S.
31
24. Stipanuk MH. Leucine and protein synthesis: mTOR and beyond. Nutr Rev 
2007;65(3):122-9.
25. Pasiakos SM, McClung JP. Supplemental dietary leucine and the skeletal muscle 
anabolic response to essential amino acids. Nutr Rev 2011;69(9):550-7. doi: 
10.1111/j.1753-4887.2011.00420.x.
26. Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS. Oral leucine 
administration stimulates protein synthesis in rat skeletal muscle. J Nutr 
2005;135(3):376-82.
27. Anthony JC, Yoshizawa F, Anthony TG, Vary TC, Jefferson LS, Kimball SR. 
Leucine stimulates translation initiation in skeletal muscle o f postabsorptive rats 
via a rapamycin-sensitive pathway. J Nutr 2000;130(10):2413-9.
28. Dodd KM, Tee AR. Leucine and mTORC1: a complex relationship. Am J Physiol 
Endocrinol and Metab 2012;302(11):E1329-42. doi:
10.1152/ajpendo.00525.2011.
29. Drummond MJ, Rasmussen BB. Leucine-enriched nutrients and the regulation of 
mammalian target of rapamycin signalling and human skeletal muscle protein 
synthesis. Curr Opin Clin Nutr Metab Care 2008;11(3):222-6. doi: 
10.1097/MCO.0b013e3282fa17fb.
30. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol 
2012;4(2). doi: 10.1101/cshperspect.a011593.
31. Vigano A, Ripamonti M, De Palma S, et al. Proteins modulation in human 
skeletal muscle in the early phase of adaptation to hypobaric hypoxia. Proteomics 
2008;8(22):4668-79. doi: 10.1002/pmic.200800232.
32. Baptista IL, Leal ML, Artioli GG, et al. Leucine attenuates skeletal muscle 
wasting via inhibition of ubiquitin ligases. Muscle Nerve 2010;41(6):800-8. doi: 
10.1002/mus.21578.
33. Schena F, Guerrini F, Tregnaghi P, Kayser B. Branched-chain amino acid 
supplementation during trekking at high altitude. The effects on loss of body 
mass, body composition, and muscle power. Eur J Appl Physiol Occup Physiol 
1992;65(5):394-8.
34. Walker TB, Smith J, Herrera M, Lebegue B, Pinchak A, Fischer J. The influence 
o f 8 weeks o f whey-protein and leucine supplementation on physical and 
cognitive performance. Int J Sport Nutr Exerc Metab 2010;20(5):409-17.
32
35. Wagenmakers AJ. Branched-chain amino acid supplementation during trekking at 
high altitude. The effects on loss of body mass, body composition and muscle 
power. Eur J Appl Physiol Occup Physiol 1993;67(1):92-5.
36. Pineau JC, Guihard-Costa AM, Bocquet M. Validation of ultrasound techniques 
applied to body fat measurement. A comparison between ultrasound techniques, 
air displacement plethysmography and bioelectrical impedance vs. dual-energy X- 
ray absorptiometry. Ann Nutr Metab 2007;51(5):421-7. doi: 10.1159/000111161.
37. Jackson AS, Pollock ML. Generalized equations for predicting body density of 
men. Br J Nutr 1978;40(3):497-504.
38. Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body 
density of women. Med Sci Sports Exerc 1980;12(3):175-81.
39. Kinanthropometry ISfhAo. International Standards for Anthropometric 
Assessment. Potchefstroom, South Africa: International Society for the 
Advancement of Kinanthropometry,, 2001.
40. Burke LM, Cox GR, Culmmings NK, Desbrow B. Guidelines for daily 
carbohydrate intake: do athletes achieve them? Sports Med 2001;31(4):267-99.
41. Sherman WM, Doyle JA, Lamb DR, Strauss RH. Dietary carbohydrate, muscle 
glycogen, and exercise performance during 7 d of training. Amer J Clin Nutr 
1993;57(1):27-31.
42. Howarth KR, Phillips SM, MacDonald MJ, Richards D, Moreau NA, Gibala MJ. 
Effect of glycogen availability on human skeletal muscle protein turnover during 
exercise and recovery. J Appl Physiol 2010;109(2):431-8. doi: 
10.1152/japplphysiol.00108.2009.
43. Rodriguez NR, DiMarco NM, Langley S, et al. Position of the American Dietetic 
Association, Dietitians of Canada, and the American College of Sports Medicine: 
Nutrition and athletic performance. J Acad Nutr Diet 2009;109(3):509-27.
44. Layman DK, Evans EM, Erickson D, et al. A moderate-protein diet produces 
sustained weight loss and long-term changes in body composition and blood 
lipids in obese adults. J Nutr 2009;139(3):514-21. doi: 10.3945/jn.108.099440.
45. Fulco CS, Friedlander AL, Muza SR, et al. Energy intake deficit and physical 
performance at altitude. Aviat Space Environ Med 2002;73(8):758-65.
